GlassScriptPhysician profile
Blaine D Buchanan
NPI 1598132961
$1,921.21
in general payments reported to CMS, 2019-2025
26 companies · $465 in 2025
The $465 reported for 2025 was more than what 79% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $328 · 2023: $403 · 2024: $267 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $480.84 | 2021-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Baxter Healthcare | $208.48 | 2022-2024 | Preveleak, Tachosil |
| Abiomed | $155.67 | 2022-2025 | Impella |
| Saphena Medical, INC. | $144.74 | 2023 | Venapax |
| Silk Road Medical, INC. | $104.98 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Janssen Pharmaceuticals, INC | $93.12 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $66.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.96 | 2024-2025 | Jardiance |
| La Jolla Pharmaceutical Company | $61.78 | 2021-2025 | Giapreza |
| Boston Scientific Corporation | $60.62 | 2021-2022 | |
| Cvrx, INC. | $51.48 | 2023-2024 | Barostim Neo System |
| Getinge USA Sales, LLC | $50.85 | 2022 | |
| Merck Sharp & Dohme LLC | $50.67 | 2025 | Keytruda, Verquvo |
| Edwards Lifesciences Corporation | $50.02 | 2021-2023 | |
| Medtronic, INC. | $38.79 | 2022-2023 | Endurant Iis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $38.44 | 2023 | Hydro Lemaitre Valvulotome, Restoreflow |
| Astrazeneca Pharmaceuticals LP | $36.30 | 2025 | Farxiga |
| Angiodynamics, INC. | $27.28 | 2021 | |
| W. L. Gore & Associates, INC. | $26.50 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Novartis Pharmaceuticals Corporation | $20.78 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.35 | 2025 | Lifevest |
| Kci USA, INC. | $18.62 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.60 | 2025 | Onpattro |
| Scpharmaceuticals INC. | $14.18 | 2025 | |
| Endologix LLC | $12.99 | 2023 | Afx2 Bifurcated Endograft System, Ovation Ix Iliac Stent Graft |
| Bard Peripheral Vascular, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blaine Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.